BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer
Open Access
- 22 February 2010
- journal article
- review article
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2010, 1-9
Abstract
In sporadic epithelial ovarian cancer (EOC), the inactivation of BRCA1 through various mechanisms is a relatively common event. BRCA1 protein dysfunction results in the breakdown of various critical pathways in the cell, notably, the DNA damage response and repair pathway. Tumors from patients withBRCA1germline mutations have an increased sensitivity to DNA damaging chemotherapeutic agents, such as cisplatin, due to defective DNA repair. Thus, inhibiting BRCA1 in sporadic EOC using novel targeted therapies is an attractive strategy for the treatment of advanced or recurrent EOC. Several classes of small molecule inhibitors that affect BRCA1 have now been tested in preclinical and clinical studies suggesting that this is a rational therapeutic approach. The aim of this paper is to provide an understanding of how BRCA1 has evolved into a promising target for the treatment of sporadic disease and to outline the main potential small molecule inhibitors of BRCA1 in EOC.Keywords
This publication has 61 references indexed in Scilit:
- A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group studyGynecologic Oncology, 2009
- Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1Clinical Cancer Research, 2009
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences, 2008
- R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignanciesBritish Journal of Cancer, 2007
- Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changesExperimental Cell Research, 2007
- A Mouse Model for the Molecular Characterization of Brca1-Associated Ovarian CarcinomaCancer Research, 2006
- Drug discovery in the ubiquitin–proteasome systemNature Reviews Drug Discovery, 2006
- The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cellsBiochemical and Biophysical Research Communications, 2005
- Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal CancerJournal of Clinical Oncology, 2005
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003